Press release
Metastatic Colorectal Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies | Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd
Metastatic Colorectal Cancer Pipeline
Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report
• DelveInsight's Metastatic Colorectal Cancer pipeline report depicts a robust space with 130+ active players working to develop 140+ pipeline therapies for Metastatic Colorectal Cancer treatment.
• The leading companies working in the Metastatic Colorectal Cancer Market include Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
• Promising Metastatic Colorectal Cancer Pipeline Therapies in the various stages of development include ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.
• September 2023: Bristol-Myers Squibb announced a study of phase 3 clinical trials for Ipilimumab, Oxaliplatin, and Leucovorin. The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.
• October 2023: Arcus Biosciences Inc. announced a study of Phase 1 & 2 clinical trials for AB680, Etrumadenant, Zimberelimab, and Bevacizumab. This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.
Request a sample and discover the recent advances in Metastatic Colorectal Cancer Treatment Drugs @ Metastatic Colorectal Cancer Pipeline Report- https://www.delveinsight.com/report-store/metastatic-colorectal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
In the Metastatic Colorectal Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Metastatic Colorectal Cancer Overview
Cancer cells may break away from a tumor in the colon and spread to other parts of the body through the bloodstream or lymphatic system. These cells may settle and form new tumors on a different organ. Even though the cancer has spread to a new organ, it is still named after the part of the body where it originally started.
Find out more about Metastatic Colorectal Cancer Therapeutics Assessment @ Metastatic Colorectal Cancer Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Metastatic Colorectal Cancer Emerging Drugs Profile
• Adagrasib (MRTX849): Mirati Therapeutics
• QL-1203: Qilu Pharmaceutical
• ZN-c3: Zentalis Pharmaceuticals
Metastatic Colorectal Cancer Pipeline Therapeutics Assessment
There are approx. 130+ key companies which are developing the Metastatic Colorectal Cancer pipeline therapies. The Metastatic Colorectal Cancer companies which have their Metastatic colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.
Learn more about the emerging Metastatic Colorectal Cancer Pipeline Therapies @ Metastatic Colorectal Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Metastatic Colorectal Cancer Pipeline Report
• Coverage- Global
• Metastatic Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Metastatic Colorectal Cancer Companies- Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, Genentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
• Metastatic Colorectal Cancer Pipeline Therapies- ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Trifluridin/Tipiracil, AB680, Etrumadenant, Zimberelimab, and others.
Dive deep into rich insights for new drugs for Metastatic Colorectal Cancer Treatment, Visit @ Metastatic Colorectal Cancer Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Metastatic colorectal cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic colorectal cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Metastatic colorectal cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. MRTX849: Mirati Therapeutics
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. AK-112: Akeso Biopharma
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. SY 5609: Syros Pharmaceuticals
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug name: Company name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Metastatic colorectal cancer Key Companies
23. Metastatic colorectal cancer Key Products
24. Metastatic colorectal cancer- Unmet Needs
25. Metastatic colorectal cancer- Market Drivers and Barriers
26. Metastatic colorectal cancer- Future Perspectives and Conclusion
27. Metastatic colorectal cancer Analyst Views
28. Metastatic colorectal cancer Key Companies
29. Appendix
For further information on the Metastatic Colorectal Cancer Pipeline therapeutics, reach out to Metastatic Colorectal Cancer Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Published Links-
https://dbook.mn.co/posts/48401881
https://lxgonline.mn.co/posts/navigating-the-landscape-of-hypertriglyceridemia-market-current-trends-and-future-prospects
https://www.penname.me/@dennydones99
https://community.fyers.in/member/7Yldtdsvui
https://spurstartup.mn.co/posts/48406045
https://pressurecooker.mn.co/posts/48406225
https://regenerative-future.mn.co/posts/navigating-the-hypertriglyceridemia-market-innovations-and-challenges
https://commiss.io/dennydones
https://www.pledgeme.co.nz/profiles/221820/
https://brave-comfort.mn.co/posts/48409148
https://gamebook.mn.co/posts/navigating-the-landscape-of-the-hypertriglyceridemia-market
https://kktix.com/user/5068280
https://network-373.mn.co/posts/48353213
https://body-imagine.mn.co/posts/48353364
https://pimpmyairgun.mn.co/posts/48353478
https://gtribe.mn.co/posts/advancements-and-opportunities-in-the-vulvar-cancer-market
https://communenour.mn.co/posts/emerging-trends-and-market-dynamics-in-vulvar-cancer-treatment
https://synkretic.mn.co/posts/understanding-the-vulvar-cancer-market-trends-challenges-and-innovations
https://jlfa2020.mn.co/members/16644457
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/peripheral-nerve-repair-devices-market
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Colorectal Cancer Pipeline, FDA Approvals, Clinical Trials Developments and Companies | Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd here
News-ID: 3347128 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Metastatic
Key Trends Reshaping the Metastatic Bone Disease Market: Advancements in Targete …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Metastatic Bone Disease Market Size Growth Forecast: What to Expect by 2025?
The market size for metastatic bone disease has seen a quick expansion in the past few years. This market will increase from a value of $17.14 billion in 2024 to $18.88 billion in 2025, with a compound…
Emerging Trends Influencing The Growth Of The Metastatic Urothelial Carcinoma Ma …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Metastatic Urothelial Carcinoma Market Size Expected to Be by 2034?
The market size for metastatic urothelial carcinoma has seen exponential growth recently. The market will expand from a worth of $1.18 billion in 2024 to $1.42 billion in 2025, with a compound annual growth rate (CAGR) of 20.2%.…
Key Influencer in the Metastatic Cancer Drugs Market 2025: Surging Prevalence Of …
How Are the key drivers contributing to the expansion of the metastatic cancer drugs market?
The escalation in the incidence of metastatic cancers will be a driving force for the expansion of the metastatic cancer drugs market. Metastatic cancer is a late-stage cancer that spreads across the body. As the number of metastatic cancer cases escalates, so does the creation of innovative drugs to treat various kinds of metastatic cancers. The…
Prominent Metastatic Breast Cancer Treatment Market Trend for 2025: Advancements …
Which drivers are expected to have the greatest impact on the over the metastatic breast cancer treatment market's growth?
The increasing occurrence of breast cancer is anticipated to boost the progression of the metastatic breast cancer treatment market. Breast cancer is a form of the disease that originates in the breast cells and is caused by abnormal cell growth in the breast, leading to the formation of a tumor. This alteration…
Major Force in the Metastatic Bone Disease Market 2025: Impact Of Bone Cancer Pr …
How Will the Metastatic Bone Disease Market Grow, and What Is the Projected Market Size?
The market size for metastatic bone disease has seen considerable growth in recent years. There is an expected increase from $17.14 billion in 2024 to $18.88 billion in 2025, with a compound annual growth rate (CAGR) of 10.1%. The substantial growth during the historical period can be credited to factors like rising aging population, heightened cancer…
Combination Therapy Strategies for Metastatic Cancer
Metastatic cancer, where cancer cells spread from the primary tumor to distant organs, presents significant treatment challenges. Combination therapy strategies have emerged as a powerful approach to enhance treatment efficacy, overcome resistance, and improve patient outcomes in metastatic cancer.
Download Report:
https://www.kuickresearch.com/report-cancer-antibody-combinations-therapy-cancer-antibody-combination-monoclonal-antibodies-combination-drug-conjugate-antibodies-combination
One of the primary goals of combination therapy in metastatic cancer is to target both the primary tumor and metastatic sites. This comprehensive approach can improve overall disease control…
